Novel Role for -Catenin in the Regulation of Cancer Cell Migration via the Induction of Hepatocyte Growth Factor Activator Inhibitor Type 1 (HAI-1)

被引:22
|
作者
Sechler, Marybeth [1 ]
Borowicz, Stanley [3 ]
Van Scoyk, Michelle [4 ]
Avasarala, Sreedevi [4 ]
Zerayesus, Sereke [4 ]
Edwards, Michael G. [2 ]
Rathinam, Manoj Kumar Karuppusamy [4 ]
Zhao, Xiangmin [4 ]
Wu, Pei-Ying [4 ]
Tang, Ke [4 ]
Bikkavilli, Rama Kamesh [4 ]
Winn, Robert A. [4 ,5 ]
机构
[1] Univ Colorado, Canc Biol Program, Aurora, CO 80045 USA
[2] Univ Colorado, Div Pulm Sci & Crit Care Med, Sch Med, Aurora, CO 80045 USA
[3] Univ Illinois, Dept Med, Div Hematol & Oncol, Chicago, IL 60612 USA
[4] Univ Illinois, Dept Med, Div Pulm Crit Care Sleep & Allergy, Chicago, IL 60612 USA
[5] Jesse Brown Vet Affairs Med Ctr, Chicago, IL 60612 USA
基金
美国国家卫生研究院;
关键词
GAMMA-CATENIN; BETA-CATENIN; LUNG-CANCER; E-CADHERIN; FACTOR/SCATTER FACTOR; SIGNALING PATHWAY; CARCINOMA-CELLS; HGF-ACTIVATOR; N-CADHERIN; PLAKOGLOBIN;
D O I
10.1074/jbc.M114.631820
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: -Catenin is a tumor suppressor in lung cancer. Results: -Catenin is a novel regulator of HAI-1 and cell migration. Conclusion: -Catenin and HAI-1 regulate cell migration and sensitize NSCLC cells to c-MET inhibitor. Significance: Targeting -catenin-mediated HAI-1 expression might be a new strategy to treat lung cancer. -catenin (Plakoglobin), a well-described structural protein functioning at the adherens junctions and desmosomes, was shown to be either lost or weakly expressed in non-small cell lung cancer (NSCLC) cells and tumor tissues. However, the tumor suppressive affects of -catenin were not fully understood. In this study, we have identified a novel role for the affects of -catenin on non-small cell lung cancer (NSCLC) cell migration. Expression of -catenin in NSCLC cells resulted in reduced cell migration as determined by both scratch assays and trans-well cell migration assays. Moreover, the affects of -catenin on cell migration were observed to be p53-dependent. Mechanistically, the anti-migratory effects seen via -catenin were driven by the expression of hepatocyte growth factor activator inhibitor Type I (HAI-1 or SPINT-1), an upstream inhibitor of the c-MET signaling pathway. Furthermore, the re-expression of -catenin sensitized NSCLC cells to c-MET inhibitor-mediated growth inhibition. Taken together, we identify -catenin as a novel regulator of HAI-1, which is a critical regulator of HGF/c-MET signaling. Therefore, targeting -catenin-mediated HAI-1 expression might be a useful strategy to sensitize NSCLC to c-MET inhibitors.
引用
收藏
页码:15610 / 15620
页数:11
相关论文
共 50 条
  • [1] Expression of Hepatocyte Growth Factor Activator Inhibitor Type-1 (HAI-1) in Prostate Cancer
    Yasuda, Kenji
    Komiya, Akira
    Watanabe, Akihiko
    Morii, Akihiro
    Oya, Takeshi
    Nagakawa, Osamu
    Fujiuchi, Yasuyoshi
    Fuse, Hideki
    ANTICANCER RESEARCH, 2013, 33 (02) : 575 - 581
  • [2] Regulation of pericellular proteolysis by hepatocyte growth factor activator inhibitor type 1 (HAI-1) in trophoblast cells
    Kohama, Kazuyo
    Kawaguchi, Makiko
    Fukushima, Tsuyoshi
    Lin, Chen-Yong
    Kataoka, Hiroaki
    HUMAN CELL, 2012, 25 (04): : 100 - 110
  • [3] Regulation of pericellular proteolysis by hepatocyte growth factor activator inhibitor type 1 (HAI-1) in trophoblast cells
    Kazuyo Kohama
    Makiko Kawaguchi
    Tsuyoshi Fukushima
    Chen-Yong Lin
    Hiroaki Kataoka
    Human Cell, 2012, 25 : 100 - 110
  • [4] The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer
    Nakamura, Keiichiro
    Abarzua, Fernando
    Hongo, Atsushi
    Kodama, Junichi
    Nasu, Yasutomo
    Kumon, Hiromi
    Hiramatsu, Yuji
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 35 (02) : 239 - 248
  • [5] Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is required for the integrity of intestinal epithelium
    Kawaguchi, Makiko
    Fukushima, Tsuyoshi
    Takeda, Naoki
    Hoshiko, Shinri
    Yorita, Kenji
    Kohama, Kazuyo
    Orikawa, Hiroshi
    Baba, Takashi
    Kataoka, Hiroaki
    FASEB JOURNAL, 2010, 24
  • [6] Serum hepatocyte growth factor activator inhibitor type I (HAI-1) and type 2 (HAI-2) in prostate cancer
    Nagakawa, O
    Yamagishi, T
    Akashi, T
    Nagaike, K
    Fuse, H
    PROSTATE, 2006, 66 (05): : 447 - 452
  • [7] Diverse roles of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in the growth of glioblastoma cells in vivo
    Miyata, S
    Uchinokura, S
    Fukushima, T
    Hamasuna, R
    Itoh, H
    Akiyama, Y
    Nakano, S
    Wakisaka, S
    Kataoka, H
    CANCER LETTERS, 2005, 227 (01) : 83 - 93
  • [8] Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front
    Nagaike, K
    Kohama, K
    Uchiyama, S
    Tanaka, H
    Chijiiwa, K
    Itoh, H
    Kataoka, H
    CANCER SCIENCE, 2004, 95 (09): : 728 - 735
  • [9] Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is required for branching morphogenesis in the chorioallantoic placenta
    Tanaka, H
    Nagaike, K
    Takeda, N
    Itoh, H
    Kohama, K
    Fukushima, T
    Miyata, S
    Uchiyama, S
    Uchinokura, S
    Shimomura, T
    Miyazawa, K
    Kitamura, N
    Yamada, G
    Kataoka, H
    MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (13) : 5687 - 5698
  • [10] Hepatocyte growth factor activator inhibitor type 1 (HAI-1) suppresses tumor growth and metastasis of pancreatic adenocarcinoma cells
    Ye, Jing-Jia
    Kawaguchi, Makiko
    Haruyama, Yukihiro
    Kanemaru, Ai
    Fukushima, Tsuyoshi
    Kataoka, Hiroaki
    CANCER RESEARCH, 2013, 73